Protocol Ledger

NCT03689712 · Phase III · COMPLETED

ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients

Interventional Phase III clinical trial protocol NCT03689712 sponsored by Galera Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-10-03 Enrollment: 455 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03689712
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)455 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03689712
Protocol FieldVerified Registry Value
NCT IdentifierNCT03689712
Consolidated Lead SponsorGalera Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment455 participants (ACTUAL)
Registered Start Date2018-10-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI